Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
Hiroshi KobayashiShintaro IwataToru WakamatsuKeiko HayakawaTsukasa YonemotoJunji WasaHiroyuki OkaTakafumi UedaSakae TanakaPublished in: Cancer (2019)
Initial trabectedin at 1.2 mg/m2 has clinically meaningful benefits for patients with L-sarcoma and certain histological subtypes of TRS.